We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TRADENAME AstraZeneca Pty Ltd
Product name
TRADENAME
Sponsor
Accepted date
Jul-2025
Active ingredients
camizestrant
Proposed indication
Camizestrant is proposed to be used with another anti-cancer medicine (called a CDK4/6 inhibitor) to treat a type of advanced breast cancer in adults. It’s for people whose cancer is hormone-sensitive (HR-positive), has low HER2 protein levels (HER2-negative), and has developed a specific genetic change (an ESR1 mutation) during their first hormone-based treatment.
Application type
A (new medicine)
Publication date
Jul-2025
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.